Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride

Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starc...

Full description

Saved in:
Bibliographic Details
Published in:TheScientificWorld 2014-01, Vol.2014 (2014), p.1-6
Main Authors: Khaira, Rekha, Saini, Vinay, Sharma, Jyoti
Format: Article
Language:English
Subjects:
Cancer therapies
Cell Line, Tumor
Chemical synthesis
Deoxycytidine - analogs & derivatives
Deoxycytidine - chemistry
Deoxycytidine - pharmacology
Dosage and administration
Drug Carriers - chemistry
Drug Carriers - pharmacology
Drug delivery systems
Drugs
Gemcitabine
Hepatocytes - drug effects
Humans
Inhibitory Concentration 50
Medical prognosis
Methods
Molecular weight
Nanoparticles
Nanoparticles - chemistry
Pancreas
Pancreatic cancer
Particle size
Production processes
Retention time
Side effects
Starch - chemistry
Studies
Technology application
Vehicles
Zeta potential
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483
cites cdi_FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483
container_end_page 6
container_issue 2014
container_start_page 1
container_title TheScientificWorld
container_volume 2014
creator Khaira, Rekha
Saini, Vinay
Sharma, Jyoti
description Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starch nanoparticles (NPs) for the delivery of gemcitabine hydrochloride that could reduce its dose related side effects and may prolong its retention time (24 hrs) for the treatment of pancreatic cancer. Nanoparticles were prepared by emulsification diffusion method with slight modifications. Size and morphology of nanoparticles were investigated. Particles were spherical in shape with slightly rough surfaces. Particle size and polydispersity index were 231.4 nm and 1.0, respectively while zeta potential of blank NPs and drug loaded NPs were found to be −11.8 mV and −9.55 mV, respectively. Percent entrapment efficiency of different formulations was around ∼54% to 65%. In vitro release profile studies showed that around 70%–83% of drug was released from different formulations. Anticancerous cell line studies were also performed in human pancreatic cell lines (MIA-PA-CA-2).
doi_str_mv 10.1155/2014/560962
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_83616b2a9c0447ff9f05d3abf83c1f23</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A413712113</galeid><doaj_id>oai_doaj_org_article_83616b2a9c0447ff9f05d3abf83c1f23</doaj_id><sourcerecordid>A413712113</sourcerecordid><originalsourceid>FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483</originalsourceid><addsrcrecordid>eNqNks-LEzEUxwdR3Lp68i4D3la6m5efMxdh6eruwqIXBW8hk7y0KTOTmplW6l9vars_Ch4kh0DeJx_eS75F8RbIOYAQF5QAvxCS1JI-KyYgmJoqzn88LyaUCTmVwMlJ8WoYloSwSoF4WZxQLmoKik0KfYUbbOOqw34sTe_K2cIkY0dM4bcZQ-zL6Msvpo8rk8ZgWxxKH1M5LrC8wjZsMG13xDV2NoymCT2WN1uXol20MQWHr4sX3rQDvjnsp8X3z5--zW6md1-vb2eXd1MrCRmnqAzloETdePCiaZyXtbDOOiVlg4xARS2zVhlOBQFfi0bV2ACislXNecVOi9u910Wz1KsUOpO2Opqg_x7ENNeHAXTFJMiGmtoSzpX3tSfCMdP4ilnwlGXXx71rtW46dDY_TTLtkfS40oeFnseNZjUVQvIseH8QpPhzjcOol3Gd-jy_hlxXcvcNj9Tc5K5C72OW2S4MVl9yYAoowK6Z839QeTnsgo09-pDPjy582F-wKQ5DQv_QOBC9C4zeBUbvA5Ppd09nfWDvE5KBsz2wCL0zv8L_2TAj6M0TOH9bzt8fv37Rkg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1564768715</pqid></control><display><type>article</type><title>Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride</title><source>Wiley-Blackwell Open Access Collection</source><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Khaira, Rekha ; Saini, Vinay ; Sharma, Jyoti</creator><contributor>Kalishwaralal, K. ; Wang, Z.</contributor><creatorcontrib>Khaira, Rekha ; Saini, Vinay ; Sharma, Jyoti ; Kalishwaralal, K. ; Wang, Z.</creatorcontrib><description>Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starch nanoparticles (NPs) for the delivery of gemcitabine hydrochloride that could reduce its dose related side effects and may prolong its retention time (24 hrs) for the treatment of pancreatic cancer. Nanoparticles were prepared by emulsification diffusion method with slight modifications. Size and morphology of nanoparticles were investigated. Particles were spherical in shape with slightly rough surfaces. Particle size and polydispersity index were 231.4 nm and 1.0, respectively while zeta potential of blank NPs and drug loaded NPs were found to be −11.8 mV and −9.55 mV, respectively. Percent entrapment efficiency of different formulations was around ∼54% to 65%. In vitro release profile studies showed that around 70%–83% of drug was released from different formulations. Anticancerous cell line studies were also performed in human pancreatic cell lines (MIA-PA-CA-2).</description><identifier>ISSN: 2356-6140</identifier><identifier>ISSN: 1537-744X</identifier><identifier>EISSN: 1537-744X</identifier><identifier>DOI: 10.1155/2014/560962</identifier><identifier>PMID: 24592173</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Cancer therapies ; Cell Line, Tumor ; Chemical synthesis ; Deoxycytidine - analogs &amp; derivatives ; Deoxycytidine - chemistry ; Deoxycytidine - pharmacology ; Dosage and administration ; Drug Carriers - chemistry ; Drug Carriers - pharmacology ; Drug delivery systems ; Drugs ; Gemcitabine ; Hepatocytes - drug effects ; Humans ; Inhibitory Concentration 50 ; Medical prognosis ; Methods ; Molecular weight ; Nanoparticles ; Nanoparticles - chemistry ; Pancreas ; Pancreatic cancer ; Particle size ; Production processes ; Retention time ; Side effects ; Starch - chemistry ; Studies ; Technology application ; Vehicles ; Zeta potential</subject><ispartof>TheScientificWorld, 2014-01, Vol.2014 (2014), p.1-6</ispartof><rights>Copyright © 2014 Rekha Khaira et al.</rights><rights>COPYRIGHT 2014 John Wiley &amp; Sons, Inc.</rights><rights>Copyright © 2014 Rekha Khaira et al. Rekha Khaira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2014 Rekha Khaira et al. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483</citedby><cites>FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1564768715/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1564768715?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,44571,53772,53774,74875</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24592173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kalishwaralal, K.</contributor><contributor>Wang, Z.</contributor><creatorcontrib>Khaira, Rekha</creatorcontrib><creatorcontrib>Saini, Vinay</creatorcontrib><creatorcontrib>Sharma, Jyoti</creatorcontrib><title>Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride</title><title>TheScientificWorld</title><addtitle>ScientificWorldJournal</addtitle><description>Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starch nanoparticles (NPs) for the delivery of gemcitabine hydrochloride that could reduce its dose related side effects and may prolong its retention time (24 hrs) for the treatment of pancreatic cancer. Nanoparticles were prepared by emulsification diffusion method with slight modifications. Size and morphology of nanoparticles were investigated. Particles were spherical in shape with slightly rough surfaces. Particle size and polydispersity index were 231.4 nm and 1.0, respectively while zeta potential of blank NPs and drug loaded NPs were found to be −11.8 mV and −9.55 mV, respectively. Percent entrapment efficiency of different formulations was around ∼54% to 65%. In vitro release profile studies showed that around 70%–83% of drug was released from different formulations. Anticancerous cell line studies were also performed in human pancreatic cell lines (MIA-PA-CA-2).</description><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Chemical synthesis</subject><subject>Deoxycytidine - analogs &amp; derivatives</subject><subject>Deoxycytidine - chemistry</subject><subject>Deoxycytidine - pharmacology</subject><subject>Dosage and administration</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Carriers - pharmacology</subject><subject>Drug delivery systems</subject><subject>Drugs</subject><subject>Gemcitabine</subject><subject>Hepatocytes - drug effects</subject><subject>Humans</subject><subject>Inhibitory Concentration 50</subject><subject>Medical prognosis</subject><subject>Methods</subject><subject>Molecular weight</subject><subject>Nanoparticles</subject><subject>Nanoparticles - chemistry</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Particle size</subject><subject>Production processes</subject><subject>Retention time</subject><subject>Side effects</subject><subject>Starch - chemistry</subject><subject>Studies</subject><subject>Technology application</subject><subject>Vehicles</subject><subject>Zeta potential</subject><issn>2356-6140</issn><issn>1537-744X</issn><issn>1537-744X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNks-LEzEUxwdR3Lp68i4D3la6m5efMxdh6eruwqIXBW8hk7y0KTOTmplW6l9vars_Ch4kh0DeJx_eS75F8RbIOYAQF5QAvxCS1JI-KyYgmJoqzn88LyaUCTmVwMlJ8WoYloSwSoF4WZxQLmoKik0KfYUbbOOqw34sTe_K2cIkY0dM4bcZQ-zL6Msvpo8rk8ZgWxxKH1M5LrC8wjZsMG13xDV2NoymCT2WN1uXol20MQWHr4sX3rQDvjnsp8X3z5--zW6md1-vb2eXd1MrCRmnqAzloETdePCiaZyXtbDOOiVlg4xARS2zVhlOBQFfi0bV2ACislXNecVOi9u910Wz1KsUOpO2Opqg_x7ENNeHAXTFJMiGmtoSzpX3tSfCMdP4ilnwlGXXx71rtW46dDY_TTLtkfS40oeFnseNZjUVQvIseH8QpPhzjcOol3Gd-jy_hlxXcvcNj9Tc5K5C72OW2S4MVl9yYAoowK6Z839QeTnsgo09-pDPjy582F-wKQ5DQv_QOBC9C4zeBUbvA5Ppd09nfWDvE5KBsz2wCL0zv8L_2TAj6M0TOH9bzt8fv37Rkg</recordid><startdate>20140101</startdate><enddate>20140101</enddate><creator>Khaira, Rekha</creator><creator>Saini, Vinay</creator><creator>Sharma, Jyoti</creator><general>Hindawi Publishing Corporation</general><general>John Wiley &amp; Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140101</creationdate><title>Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride</title><author>Khaira, Rekha ; Saini, Vinay ; Sharma, Jyoti</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Chemical synthesis</topic><topic>Deoxycytidine - analogs &amp; derivatives</topic><topic>Deoxycytidine - chemistry</topic><topic>Deoxycytidine - pharmacology</topic><topic>Dosage and administration</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Carriers - pharmacology</topic><topic>Drug delivery systems</topic><topic>Drugs</topic><topic>Gemcitabine</topic><topic>Hepatocytes - drug effects</topic><topic>Humans</topic><topic>Inhibitory Concentration 50</topic><topic>Medical prognosis</topic><topic>Methods</topic><topic>Molecular weight</topic><topic>Nanoparticles</topic><topic>Nanoparticles - chemistry</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Particle size</topic><topic>Production processes</topic><topic>Retention time</topic><topic>Side effects</topic><topic>Starch - chemistry</topic><topic>Studies</topic><topic>Technology application</topic><topic>Vehicles</topic><topic>Zeta potential</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khaira, Rekha</creatorcontrib><creatorcontrib>Saini, Vinay</creatorcontrib><creatorcontrib>Sharma, Jyoti</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest - Health &amp; Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>TheScientificWorld</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khaira, Rekha</au><au>Saini, Vinay</au><au>Sharma, Jyoti</au><au>Kalishwaralal, K.</au><au>Wang, Z.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride</atitle><jtitle>TheScientificWorld</jtitle><addtitle>ScientificWorldJournal</addtitle><date>2014-01-01</date><risdate>2014</risdate><volume>2014</volume><issue>2014</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>2356-6140</issn><issn>1537-744X</issn><eissn>1537-744X</eissn><abstract>Gemcitabine (2,2-difluorodeoxycytidine) is a deoxycytidine analog, currently being used as a first-choice drug in pancreatic metastatic cancer. Gemcitabine is administered weekly as 30-minute infusion with starting dose ranging from 800 to 1250 mg/m2. The aim of the present work was to develop starch nanoparticles (NPs) for the delivery of gemcitabine hydrochloride that could reduce its dose related side effects and may prolong its retention time (24 hrs) for the treatment of pancreatic cancer. Nanoparticles were prepared by emulsification diffusion method with slight modifications. Size and morphology of nanoparticles were investigated. Particles were spherical in shape with slightly rough surfaces. Particle size and polydispersity index were 231.4 nm and 1.0, respectively while zeta potential of blank NPs and drug loaded NPs were found to be −11.8 mV and −9.55 mV, respectively. Percent entrapment efficiency of different formulations was around ∼54% to 65%. In vitro release profile studies showed that around 70%–83% of drug was released from different formulations. Anticancerous cell line studies were also performed in human pancreatic cell lines (MIA-PA-CA-2).</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>24592173</pmid><doi>10.1155/2014/560962</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2356-6140
ispartof TheScientificWorld, 2014-01, Vol.2014 (2014), p.1-6
issn 2356-6140
1537-744X
1537-744X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_83616b2a9c0447ff9f05d3abf83c1f23
source Wiley-Blackwell Open Access Collection; Open Access: PubMed Central; Publicly Available Content Database
subjects Cancer therapies
Cell Line, Tumor
Chemical synthesis
Deoxycytidine - analogs & derivatives
Deoxycytidine - chemistry
Deoxycytidine - pharmacology
Dosage and administration
Drug Carriers - chemistry
Drug Carriers - pharmacology
Drug delivery systems
Drugs
Gemcitabine
Hepatocytes - drug effects
Humans
Inhibitory Concentration 50
Medical prognosis
Methods
Molecular weight
Nanoparticles
Nanoparticles - chemistry
Pancreas
Pancreatic cancer
Particle size
Production processes
Retention time
Side effects
Starch - chemistry
Studies
Technology application
Vehicles
Zeta potential
title Development and Characterization of Nanoparticles for the Delivery of Gemcitabine Hydrochloride
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T08%3A57%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20Characterization%20of%20Nanoparticles%20for%20the%20Delivery%20of%20Gemcitabine%20Hydrochloride&rft.jtitle=TheScientificWorld&rft.au=Khaira,%20Rekha&rft.date=2014-01-01&rft.volume=2014&rft.issue=2014&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=2356-6140&rft.eissn=1537-744X&rft_id=info:doi/10.1155/2014/560962&rft_dat=%3Cgale_doaj_%3EA413712113%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c600t-e7a241759bf1f5bbdf695cdcd766be30182c3cc7a42501f95b79eb1ee7c894483%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1564768715&rft_id=info:pmid/24592173&rft_galeid=A413712113&rfr_iscdi=true